Giant Cell Arteritis
Information
- Disease name
- Giant Cell Arteritis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04474847 | Active, not recruiting | Phase 3 | Abatacept for the Treatment of Giant Cell Arteritis | March 15, 2021 | December 2026 |
| NCT05168475 | Active, not recruiting | Phase 2 | Biologics in Refractory Vasculitis | July 14, 2021 | June 2024 |
| NCT05623592 | Active, not recruiting | Phase 2 | Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis | November 23, 2022 | November 2025 |
| NCT04633447 | Active, not recruiting | Phase 2 | A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis | December 10, 2020 | June 30, 2025 |
| NCT04519580 | Active, not recruiting | Improved Diagnostics and Monitoring of Polymyalgia Rheumatica | September 14, 2020 | June 30, 2027 | |
| NCT04071691 | Active, not recruiting | PET Imaging of Giant Cell and Takayasu Arteritis | June 25, 2019 | August 2023 | |
| NCT01450137 | Completed | Phase 2 | Tocilizumab for Patients With Giant Cell Arteritis | September 2011 | September 2015 |
| NCT01588483 | Completed | Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis | March 1, 2012 | April 1, 2023 | |
| NCT01791153 | Completed | Phase 3 | An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) | July 22, 2013 | June 4, 2018 |
| NCT01795456 | Completed | Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis | August 2010 | January 2014 | |
| NCT01910038 | Completed | Phase 2 | Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. | November 8, 2013 | June 13, 2016 |
| NCT02176070 | Completed | Reproductive Health in Men and Women With Vasculitis | February 2011 | March 2012 | |
| NCT02190916 | Completed | Vasculitis Illness Perception (VIP) Study | October 2011 | October 2013 | |
| NCT02190929 | Completed | Educational Needs of Patients With Systemic Vasculitis | March 2012 | February 2014 | |
| NCT02190942 | Completed | VCRC Patient Contact Registry Patient-Reported Data Validation Study | May 2014 | June 18, 2019 | |
| NCT00004686 | Completed | Phase 2 | Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis | February 1994 | September 1999 |
| NCT00138983 | Completed | Phase 3 | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. | May 2000 | November 2003 |
| NCT00305539 | Completed | Phase 3 | HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis | May 2006 | May 2011 |
| NCT00430807 | Completed | Phase 3 | Hydroxychloroquine in Giant Cell Arteritis | January 2002 | December 2006 |
| NCT00556439 | Completed | Phase 2 | Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis | December 2008 | August 2015 |
| NCT00974883 | Completed | Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) | June 2010 | December 2014 | |
| NCT02703922 | Completed | N/A | Validation of a Diagnostic Algorithm of Giant Cell Arteritis | August 29, 2016 | February 10, 2022 |
| NCT02771483 | Completed | Giant Cell Arteritis and PET Scan (GAPS) Study | May 15, 2016 | January 28, 2020 | |
| NCT03202368 | Completed | Phase 3 | An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) | October 25, 2017 | August 21, 2019 |
| NCT03285945 | Completed | FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment | October 2014 | September 2016 | |
| NCT03409913 | Completed | Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA | October 1, 2014 | December 31, 2017 | |
| NCT03410290 | Completed | Journey of Patients With Vasculitis From First Symptom to Diagnosis | January 11, 2018 | May 21, 2018 | |
| NCT03658889 | Completed | Assessment of Giant Cell Arteritis Medical Practices in France | August 2, 2018 | November 9, 2018 | |
| NCT03726749 | Completed | Phase 4 | Tocilizumab Plus a Short Prednisone Taper for GCA | November 28, 2018 | December 29, 2021 |
| NCT03745586 | Completed | Phase 1/Phase 2 | Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab | December 1, 2018 | March 1, 2021 |
| NCT03765424 | Completed | Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis | October 1, 2014 | December 31, 2018 | |
| NCT03765788 | Completed | Phase 2 | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | January 30, 2019 | June 8, 2021 |
| NCT03812302 | Completed | Phase 2 | Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) | September 9, 2019 | September 30, 2023 |
| NCT03827018 | Completed | Phase 2 | KPL-301 for Subjects With Giant Cell Arteritis | September 20, 2018 | November 25, 2020 |
| NCT03923738 | Completed | Phase 1 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). | August 5, 2019 | November 12, 2020 |
| NCT04142515 | Completed | Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease) | February 1, 2020 | March 31, 2021 | |
| NCT04204512 | Completed | Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis | December 17, 2019 | August 24, 2020 | |
| NCT04204876 | Completed | Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course | May 28, 2020 | August 5, 2023 | |
| NCT04554290 | Completed | Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy | August 1, 2020 | December 30, 2022 | |
| NCT04885829 | Completed | Phase 1 | Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers | May 31, 2021 | May 4, 2023 |
| NCT05246540 | Completed | Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis | January 1, 2020 | December 1, 2021 | |
| NCT04012905 | Not yet recruiting | Phase 3 | Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering | November 5, 2020 | January 2027 |
| NCT06244069 | Not yet recruiting | Clonal Hematopoiesis in Giant Cell Arteritis | March 2024 | March 2031 | |
| NCT06271018 | Not yet recruiting | TocILizumab in aorTitis in GCA (TILT) | April 1, 2024 | April 1, 2028 | |
| NCT05749094 | Not yet recruiting | Optic Nerve Sheath Ultrasound in Giant Cell Arteritis | March 2024 | August 2027 | |
| NCT05703763 | Not yet recruiting | Applanation Tonometry in the Diagnosis of Giant Cell Arteritis | March 2024 | August 2027 | |
| NCT06335888 | Not yet recruiting | Phase 2 | A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis | June 2024 | May 2029 |
| NCT05854927 | Not yet recruiting | Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA) | January 2024 | June 2027 | |
| NCT06037460 | Recruiting | Phase 3 | TocilizuMab discontinuAtion in GIant Cell Arteritis | May 13, 2024 | November 2028 |
| NCT02257866 | Recruiting | Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis | September 29, 2014 | January 1, 2050 | |
| NCT04102930 | Recruiting | Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) | June 10, 2005 | February 1, 2025 | |
| NCT05865054 | Recruiting | Vessel Wall Enhancement in Giant Cell Arteritis | July 29, 2020 | July 2026 | |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT06130540 | Recruiting | Phase 1 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | March 27, 2024 | July 25, 2025 |
| NCT05904301 | Recruiting | Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases | June 21, 2023 | June 30, 2028 | |
| NCT05935709 | Recruiting | DANIsh VASculitis Database (DANIVAS) | November 10, 2023 | December 31, 2051 | |
| NCT06004154 | Recruiting | Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim) | November 28, 2023 | April 2027 | |
| NCT06011512 | Recruiting | Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. | August 1, 2023 | June 1, 2026 | |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT03892785 | Recruiting | Phase 3 | MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | January 27, 2020 | March 2027 |
| NCT01241305 | Recruiting | One-Time DNA Study for Vasculitis | October 2010 | August 2027 | |
| NCT06279065 | Recruiting | Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis | February 29, 2024 | February 2028 | |
| NCT04888221 | Recruiting | Phase 3 | Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement | September 24, 2021 | March 2024 |
| NCT05000138 | Recruiting | FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis | June 10, 2022 | June 30, 2025 | |
| NCT06460142 | Recruiting | Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic | September 1, 2023 | September 30, 2027 | |
| NCT05380453 | Recruiting | Phase 3 | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | September 21, 2022 | November 13, 2025 |
| NCT02967068 | Recruiting | VCRC Tissue Repository | November 2016 | December 2025 | |
| NCT05435781 | Recruiting | Phase 4 | Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency | June 7, 2022 | March 1, 2028 |
| NCT05663333 | Recruiting | Histopathological Analysis of Temporal Artery Biopsy Following Dynamic Full-field Optical Coherence Tomography, a Comparison to Conventional Histopathological Findings in Patients With Suspected Giant Cell Arteritis (DOCTA) | January 26, 2023 | July 31, 2024 | |
| NCT03482479 | Recruiting | Phase 2 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | February 4, 2019 | December 31, 2024 |
| NCT04335747 | Terminated | COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases | April 23, 2020 | July 1, 2021 | |
| NCT02531633 | Terminated | Phase 3 | Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis | October 16, 2015 | March 21, 2018 |
| NCT04049071 | Terminated | TARGET GCAT Registry | May 13, 2019 | June 30, 2020 | |
| NCT02955147 | Terminated | Phase 1/Phase 2 | Ustekinumab for the Treatment of Giant Cell Arteritis | December 1, 2016 | September 19, 2019 |
| NCT03600805 | Terminated | Phase 3 | Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA | November 20, 2018 | November 24, 2020 |
| NCT03656627 | Terminated | Phase 1 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | June 27, 2019 | March 18, 2021 |
| NCT00076726 | Terminated | Phase 2 | A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis | November 2003 | July 2005 |
| NCT02902731 | Unknown status | Phase 3 | Giant Cell Arteritis and Anakinra Trial | May 11, 2017 | March 2022 |
| NCT04239196 | Unknown status | Phase 2 | Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA | September 10, 2020 | December 10, 2022 |
| NCT02985424 | Unknown status | Polymyalgia Rheumatica and Giant Cell Arteritis | May 2017 | February 2020 | |
| NCT00006055 | Unknown status | N/A | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | March 2000 | |
| NCT01400464 | Unknown status | Phase 4 | Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis | July 2009 | December 2014 |
| NCT05045001 | Unknown status | Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases | June 2, 2021 | December 2022 | |
| NCT03244709 | Unknown status | Phase 4 | Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. | January 1, 2015 | December 31, 2017 |
| NCT01066208 | Unknown status | American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis | January 2011 | December 2018 | |
| NCT02333708 | Unknown status | Study of Circulating Microparticles in Giant Cell Arteritis | September 2015 | November 2023 | |
| NCT02523625 | Unknown status | Giant Cell Arteritis: Improving Use of Ultrasound Evaluation | October 2015 | June 2018 | |
| NCT04664465 | Unknown status | PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS | March 18, 2021 | March 18, 2024 | |
| NCT05248906 | Unknown status | Giant Cell Arteritis - Optimization of Diagnostics | March 19, 2021 | January 1, 2023 | |
| NCT04397237 | Unknown status | Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe | June 10, 2020 | January 2021 | |
| NCT03192969 | Withdrawn | Phase 3 | A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) | July 15, 2017 | November 23, 2021 |
- OrphaNumber from OrphaNet (Orphanet)
- 397
- MeSH unique ID (MeSH (Medical Subject Headings))
- D013700